Abstract | UNLABELLED: METHODS: Twenty-seven patients, pretreated with (90)Y-DOTATOC, were included. The mean time between the last treatment with (90)Y-DOTATOC and (177)Lu-DOTATOC was 15.4 +/- 7.8 mo (SD). All patients were injected with 7,400 MBq of (177)Lu-DOTATOC. Restaging was performed after 8-12 wk. Hematotoxicity or renal toxicity of World Health Organization grade 1 or 2 was not an exclusion criterion. RESULTS:
Creatinine levels increased significantly, from 66 +/- 14 micromol/L to 100 +/- 44 micromol/L (P < 0.0001), after (90)Y-DOTATOC therapy. The mean hemoglobin level dropped from 131 +/- 14 to 117 +/- 13 g/L (P < 0.0001) after (90)Y-DOTATOC therapy. (177)Lu-DOTATOC therapy was well tolerated. No serious adverse events occurred. The mean absorbed doses were 413 +/- 159 mGy for the whole body, 3.1 +/- 1.5 Gy for the kidneys, and 61 +/- 5 mGy for the red marrow. After restaging, we found a partial remission in 2 patients, a minor response in 5 patients, stable disease in 12 patients, and progressive disease in 8 patients. Mean hemoglobin and creatinine levels did not change significantly. CONCLUSION:
(177)Lu-DOTATOC therapy in patients with relapse after (90)Y-DOTATOC treatment is feasible, safe, and efficacious. No serious adverse events occurred.
|
Authors | Flavio Forrer, Helena Uusijärvi, Daniel Storch, Helmut R Maecke, Jan Mueller-Brand |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 46
Issue 8
Pg. 1310-6
(Aug 2005)
ISSN: 0161-5505 [Print] United States |
PMID | 16085587
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 177Lu-octreotide, DOTA(0)-Tyr(3)-
- Radiopharmaceuticals
- 90Y-octreotide, DOTA-Tyr(3)-
- Octreotide
|
Topics |
- Adult
- Aged
- Carcinoma, Neuroendocrine
(diagnostic imaging, secondary)
- Feasibility Studies
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(diagnostic imaging, secondary)
- Octreotide
(analogs & derivatives, therapeutic use)
- Radionuclide Imaging
- Radiopharmaceuticals
(therapeutic use)
- Treatment Outcome
|